The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFaron Pharma Regulatory News (FARN)

Share Price Information for Faron Pharma (FARN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 155.00
Bid: 150.00
Ask: 160.00
Change: 0.00 (0.00%)
Spread: 10.00 (6.667%)
Open: 155.00
High: 155.00
Low: 155.00
Prev. Close: 155.00
FARN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

27 Mar 2017 09:23

RNS Number : 6032A
Faron Pharmaceuticals Oy
27 March 2017
 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi
 

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii

Faron Pharmaceuticals Oy

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

X

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

3. Full name of person(s) subject to thenotification obligation: iii

City Financial Investment Company Limited, acting as Investment Manager and Authorised Corporate Director of the City Financial Absolute Equity Fund

 

4. Full name of shareholder(s)  (if different from 3.):iv

BNY Mellon Trust and Depositary as Trustee to the City Financial Absolute Equity Fund

 

5. Date of the transaction and date onwhich the threshold is crossed orreached: v

21 March 2017

6. Date on which issuer notified:

24 March 2017

7. Threshold(s) that is/are crossed orreached: vi, vii

5%

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

FI4000153309

 

1,440,530

1,440,530

1,140,530

1,140,530

0

4.11%

0

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate xiii

Exercise/Conversion Period xiv

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date xvii

Exercise/Conversion period xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 

 

 

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

1,140,530

4.11%

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi

 

The voting rights are managed and controlled by City Financial Investment Company Limited, Investment manager and ACD to the City Financial Absolute Equity Fund.

Proxy Voting:

10. Name of the proxy holder:

11. Number of voting rights proxy holder will cease to hold:

12. Date on which proxy holder will cease to hold voting rights:

13. Additional information:

14. Contact name:

Ben Ellenbogen

15. Contact telephone number:

0207 451 9600

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLMMGZFRNKGNZG
Date   Source Headline
6th Nov 20183:52 pmRNSPDMR Dealings
23rd Oct 201811:05 amRNSSecond Price Monitoring Extn
23rd Oct 201811:00 amRNSPrice Monitoring Extension
23rd Oct 20189:06 amRNSSecond Price Monitoring Extn
23rd Oct 20189:00 amRNSPrice Monitoring Extension
22nd Oct 20183:00 pmRNSINTEREST trial update presented at ESICM
18th Sep 20189:23 amRNSDirector/PDMR Shareholding
17th Sep 20187:00 amRNSFaron announces CTA filing for Clevegen
13th Sep 20187:00 amRNSInterim Results
12th Sep 20187:00 amRNSNew data published on Clever-1 function
8th Aug 201811:05 amRNSSecond Price Monitoring Extn
8th Aug 201811:00 amRNSPrice Monitoring Extension
8th Aug 20187:00 amRNSNotice of Interim Results
9th Jul 20188:45 amRNSHolding(s) in Company
28th Jun 20187:00 amRNSClevegen successful toxicity studies
22nd Jun 20187:00 amRNSHoldings in Company
21st Jun 20183:58 pmRNSDirector/PDMR Shareholding
21st Jun 20189:00 amRNSPrice Monitoring Extension
21st Jun 20187:40 amRNSDirector/PDMR Shareholding
20th Jun 20182:05 pmRNSSecond Price Monitoring Extn
20th Jun 20182:00 pmRNSPrice Monitoring Extension
20th Jun 20188:43 amRNSHolding(s) in Company
18th Jun 20183:42 pmRNSHoldings in Company
15th Jun 20184:40 pmRNSSecond Price Monitoring Extn
15th Jun 20184:35 pmRNSPrice Monitoring Extension
14th Jun 201811:05 amRNSSecond Price Monitoring Extn
14th Jun 201811:00 amRNSPrice Monitoring Extension
14th Jun 20187:00 amRNSBiomarker analysis of Phase III INTEREST trial
31st May 20182:33 pmRNSResult of AGM
31st May 20187:00 amRNSAGM Statement
16th May 20185:53 pmRNSPDMR Shareholding
15th May 20183:14 pmRNSDirector/PDMR Shareholding
15th May 20182:05 pmRNSSecond Price Monitoring Extn
15th May 20182:00 pmRNSPrice Monitoring Extension
15th May 20181:16 pmRNSHoldings in Company
11th May 20184:51 pmRNSHolding(s) in Company
11th May 20181:37 pmRNSHolding(s) in Company
11th May 20181:34 pmRNSHolding(s) in Company
11th May 20187:00 amRNSUpdate on the Phase III INTEREST trial
10th May 201810:05 amRNSNotice of AGM
9th May 20184:40 pmRNSSecond Price Monitoring Extn
9th May 20184:35 pmRNSPrice Monitoring Extension
9th May 201812:54 pmRNSHoldings in Company
8th May 20189:05 amRNSSecond Price Monitoring Extn
8th May 20189:00 amRNSPrice Monitoring Extension
8th May 20187:00 amRNSTop line data from the Phase III INTEREST trial
8th May 20187:00 amRNSFinal Results for the year ended 31 December 2017
25th Apr 201812:43 pmRNSHoldings in Company
21st Mar 20187:00 amRNSNotice of Full Year Results
6th Mar 201812:54 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.